Clinical Immunotherapeutics

, Volume 4, Issue 3, pp 197–206 | Cite as

Appropriate Use of Varicella Vaccine

  • Barbara Watson
  • Jill A. Foster
Practical Therapeutics


Varicella (chickenpox) is the last major exanthem of childhood not yet controlled by immunisation. One reason for the delay in recognising the need for a vaccine has been the perception that varicella is a trivial disease. Background data to dispel this perception are presented. This is followed by descriptions of the cellular and humoral immune responses to the wild virus, which led to the development of the vaccine.

Extensive clinical trials have been conducted in Japan, Belgium and the US to evaluate the safety, immunogenicity and transmissibility of the virus used in the live attenuated vaccine, including comparative studies of various vaccine preparations, dose titration, efficacy (of which there is a single placebo-controlled study), consistency and persistency of the immune response.

The results of these trials guide recommendations for the proposed use of the vaccine in the following patient groups: (a) healthy children — if all children are eventually immunised routinely against varicella, most children who become immunocompromised will have already been immunised, as is the case with the existing childhood disease vaccines; (b) healthy adolescents and adults; (c) immunocompromised individuals; (d) the elderly, including adults over 40 years of age, to prevent zoster (shingles) by boosting the cell-mediated immune system; (e) individuals exposed to the virus, as post-exposure prophylaxis in preference to the use of varicella zoster immune globulin.

The results of the trials indicate what reactions to expect following use in each group. Surveillance procedures must be put into place to track the baseline incidence of varicella prior to general use of the varicella vaccine and to follow the patterns of disease after introduction of vaccination.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Preblud SR. Varicella: complications and costs. Pediatrics 1986; 7: 604–8Google Scholar
  2. 2.
    Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271: 375–81PubMedCrossRefGoogle Scholar
  3. 3.
    Fleisher G, Henry W, Mcsorley M, et al. Life threatening complications of varicella. Am J Dis Child 1982; 135: 896–9Google Scholar
  4. 4.
    Brunell P. Varicella in pregnancy, the fetus, and the newborn: problems in management. J Infect Dis 1992; 166 Suppl. 1: S42–7PubMedCrossRefGoogle Scholar
  5. 5.
    Davison AJ, Scott NE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986; 67: 1159–86Google Scholar
  6. 6.
    Grose C, Litwin V. Immunology of the varicella-zoster virus glycoproteins. J Infect Dis 1988; 157: 877–81PubMedCrossRefGoogle Scholar
  7. 7.
    Weigle KA, Grose C. Molecular dissection of the humoral response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection and reactivation. J Infect Dis 1984; 149: 741–9PubMedCrossRefGoogle Scholar
  8. 8.
    Arvin AM, Pollard RB, Rasmussen LE, et al. Cellular and humoral immunity in lymphoma patients. J Clin Invest 1980; 65: 896–78CrossRefGoogle Scholar
  9. 9.
    Patel PA, Yoonessi S, O’Malley J, et al. Cell-mediated immunity to varicella zoster virus infection in subjects with lymphoma or leukemia. J Pediatr 1979; 94: 223–30PubMedCrossRefGoogle Scholar
  10. 10.
    Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 1992; 166 Suppl. 1: S35–41PubMedCrossRefGoogle Scholar
  11. 11.
    Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987; 7: 174–8PubMedCrossRefGoogle Scholar
  12. 12.
    Takahashi M, Okuno Y, Otsuka T, et al. Development of a live attenuated varicella vaccine. Biken J 1975; 18: 25–33PubMedGoogle Scholar
  13. 13.
    Takahashi M. Current status and prospects of live varicella vaccine. Vaccine 1992; 10: 1007–14PubMedCrossRefGoogle Scholar
  14. 14.
    Takahashi M, Otsuka T, Okuno Y. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2: 1288–90PubMedCrossRefGoogle Scholar
  15. 15.
    Arbeter AM, Starr SE, Preblud SR, et al. Varicella vaccine trials in healthy children: a summary of comparative and follow-up studies. Am J Dis Child 1984; 138: 434–8PubMedGoogle Scholar
  16. 16.
    Balfour H, Suarez C, Gilmore B, et al. Varicella vaccine trial in normal children: immunogenicity and side effects. Clin Res 1985; 33: 885AGoogle Scholar
  17. 17.
    Brunell PA, Taylor-Wiedeman J, Shehab ZM, et al. Administration of varicella vaccine to children with leukemia. Biken J 1984; 27: 83–8PubMedGoogle Scholar
  18. 18.
    Johnson CE, Shurin PA, Fattlar D, et al. Live attenuated varicella vaccine in healthy 12–24 month-old children. Pediatrics 1988; 81: 512–7PubMedGoogle Scholar
  19. 19.
    Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. N Engl J Med 1984; 310: 1410–5CrossRefGoogle Scholar
  20. 20.
    Andre FE. Summary of clinical studies with the Oka live attenuated varicella vaccine produced by Smith Kline-RIT. Biken J 1984; 27: 89PubMedGoogle Scholar
  21. 21.
    White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescent: results from clinical trials, 1987 to 1989. Pediatrics 1991; 87: 604–10PubMedGoogle Scholar
  22. 22.
    Arbeter A, Starr SE, Plotkin SP. Varicella vaccine in healthy children and adults. Pediatrics 1986; 78: 748–56PubMedGoogle Scholar
  23. 23.
    Watson BM, Jeller PM, Ellis RW, et al. Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis 1990; 162: 794–9PubMedCrossRefGoogle Scholar
  24. 24.
    Hayward AR, Herberger M. Lymphocyte responses to varicella-zoster virus in the elderly. J Clin Immunol 1987; 7: 174–8PubMedCrossRefGoogle Scholar
  25. 25.
    Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. In pressGoogle Scholar
  26. 26.
    Kuter BJ, Weibal RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children — final report of a 2-year efficacy study and 7-year follow-up. Vaccine 1991; 9: 643–7PubMedCrossRefGoogle Scholar
  27. 27.
    Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of varicella vaccine. Pediatrics 1985; 75: 667–71PubMedGoogle Scholar
  28. 28.
    Asano Y, Suga S, Yoshikawa T, et al. Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994; 94: 524–6PubMedGoogle Scholar
  29. 29.
    Watson B, Gupta R, Randall T, et al. Persistence of cell-mediated and humoral immune responses in healthy children immunized with the live attenuated varicella vaccine. J Infect Dis 1994; 169: 197–9PubMedCrossRefGoogle Scholar
  30. 30.
    Gershon AA, Steinberg S. NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J Infect Dis 1990; 161: 661–6PubMedCrossRefGoogle Scholar
  31. 31.
    Bergen RE, Diaz PS, Arvin A. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis 1990; 162: 1049–54PubMedCrossRefGoogle Scholar
  32. 32.
    Gershon AA, Steinberg SP, and the Varicella Vaccine Collaborative Study Group of the National Institute of Allergy and Infectious Diseases. Persistence of immunity to varicella in children with leukemia immunized with live varicella vaccine. N Engl J Med 1989; 320: 892–7PubMedCrossRefGoogle Scholar
  33. 33.
    Gershon AA, Steinberg SP, Gelb L, et al. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 1984; 252: 355–62PubMedCrossRefGoogle Scholar
  34. 34.
    Gershon AA, Steinberg SP, Gelb L, et al. A multicenter trial of live attenuated varicella vaccine in children with leukemia in remission. Postgrad Med J 1985; 61 Suppl.: 73–8PubMedCrossRefGoogle Scholar
  35. 35.
    Tsolia M, Gershon A, Steinberg SP, et al. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in the transmission of varicella-zoster virus. J Pediatr 1990; 116: 184–9PubMedCrossRefGoogle Scholar
  36. 36.
    Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 1983; 148: 200–5PubMedCrossRefGoogle Scholar
  37. 37.
    White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11: 19–22PubMedCrossRefGoogle Scholar
  38. 38.
    Brunell PA, Novelli VM, Keller DM, et al. Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response. J Infect Dis 1987; 156(3): 430–5PubMedCrossRefGoogle Scholar
  39. 39.
    Watson B, Piercy S, Plotkin SA, et al. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91: 17–22PubMedGoogle Scholar
  40. 40.
    Merck & Co. Varivax® [varicella virus vaccine live (Oka/Merck)]: package insert. West Point, PA: Merck & Co., 1995Google Scholar
  41. 41.
    Gershon AA, Larussa P, Hardy I, et al. Varicella vaccine: the American experience. J Infect Dis 1992 Aug; 166 Suppl. 1: 663–9Google Scholar
  42. 42.
    Horiuchi K. Chickenpox vaccination of healthy children: immunological and clinical responses and protective effect in 1978–1982. Biken J 1984; 27: 37–8PubMedGoogle Scholar
  43. 43.
    Katsushima N, Yazaki N, Sakamoto M. Effect and follow-up study on varicella vaccine. Biken J 1984; 27: 51–8PubMedGoogle Scholar
  44. 44.
    Arbeter AM, Baker L, Starr SE, et al. Combination measles, mumps, rubella, and varicella vaccine. Pediatrics 1986; 78 Suppl.: 742–7PubMedGoogle Scholar
  45. 45.
    Brunell PA, Novelli VM, Lipton SV, et al. Combination vaccine against measles, mumps, rubella, and varicella. Pediatrics 1988; 81: 779–84PubMedGoogle Scholar
  46. 46.
    Weiler TH. Varicella and herpes zoster: a perspective and overview. J Infect Dis 1992; 166 Suppl.: 1–6CrossRefGoogle Scholar
  47. 47.
    Hardy IB, Gershon AA, Larussa PS, et al. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med 1991; 325: 1545–50PubMedCrossRefGoogle Scholar
  48. 48.
    Meier JL, Straus SE. Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J Infect Dis 1992; 166 Suppl.: 13–23CrossRefGoogle Scholar
  49. 49.
    Lawrence R, Geshon A, Steinberg S, et al. The risk of zoster in leukemic children who received live attenuated varicella vaccine. N Engl J Med 1988; 318: 543–8PubMedCrossRefGoogle Scholar
  50. 50.
    Brunell PA, Taylor-Wiedeman J, Geiser C, et al. Risk of herpes zoster in children with leukemia: varicella vaccine compared with a history of chickenpox. Pediatrics 1986; 77: 53–6PubMedGoogle Scholar
  51. 51.
    Levin DL, Hayward AR. Decreased herpetic neuralgia in patients immunized with VZV vaccine. Second International Conference for VZV: 1995 July 6–8; ParisGoogle Scholar
  52. 52.
    American Academy of Pediatrics. Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995; 95: 791–6Google Scholar
  53. 53.
    Ross LF, Lantos JD. Immunisation against chickenpox: better to confine immunisation to those at high risk. BMJ 1995; 310: 2–3PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Barbara Watson
    • 1
  • Jill A. Foster
    • 1
  1. 1.The Children’s Hospital of Philadelphia and the University of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations